预约演示
Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresibBET inhibitor pelabresib: filing
临床3期临床结果并购引进/卖出
When MorphoSys made clear it already had another offer on the table, Novartis said it would “move quickly” to stay in the game.
Novartishanding over 2.7 billion euros ($2.9 billion) cash tMorphoSys the German biotech in February, the star of the show in Novartis’ eyes was always pelabresib, according to deal-related documents published yesterday. MorphoSys had been testing the BET inhibitor in combination with Incyte’s Jakafi in patients with myelofibrosis.
MorphoSys’ relationship with Novartis dates back decades and was strengthened in 2022 when the pharma paid $23 million in cashNovartis rights to the biopelabresibclinical cancer program. But as far as yesterday’s documentMorphoSyscerned, the story realBET inhibitorBETbegins at the BIO InternationalIncytentiJakafiJune 2023, when exmyelofibrosis companies met up to discuss “potential strategic opportunities.”
MorphoSysompanies did discussNovartissib, although Novartis didn’t put any offer on the table at this stage. Over the following months, the Big Pharma made it increasinglycancer it was interested in the drug, with those intentions becoming more concrete after MorphoSys published topline data from a phase 3 trial in November 2023 showing that pelabresib hit one primary endpoint on spleen volume reduction but missed another on significantly beating placebo on reducing symptoms.
By late December, Novartis waspelabresibnuary’s J.PNovartis Healthcare Conference as the best time to bring the companies’ respective CEOs together to discuss a deal. But when MorphoSys made it clear it already had another offer on the table, Novartis stressedMorphoSyswould “move quickly” to stay in the game.pelabresib
Novartis’ initial Novartiss sent on Jan. 3—to acquire all of MorphoSys’ shares for 55 euros ($58) apiece in cash. With a view to wrapping up the deal in two weeks, negotiationsMorphoSyshead until Jan. 12, when Novartis threw a curveball—ratherNovartisy the biotech outright, could the Big Pharma just pick up the pelabresib program via an acquisition of MorphoSys’ Constellation Pharmaceuticals unit?
Novartisen the proposal, Novartis said it might be willing toMorphoSysgher price for pelabresib alone than if it came entangled with the rest of MorphoSys. But the biotech didn’t bite, and two days later NovartNovartisubmitted an updated offer of 68 euros ($75) per share for the whole company. This would end up pelabresibfinalized offer, conditional onMorphoSyss Constellation Pharmaceuticalssset—lymphoma med Monjuvi—to longtime partner Incyte.
Novartis executives made Novartist of the fact that pelabresib was the real prize whepelabresibt public with the deal in February. “We are exciteMorphoSyshe opportunity of bringing pelabresib, a potentialNovartisneration treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer,” the pharma’s MorphoSysical officer Shreeram Aradhye, M.D.lymphomat the time.Incyte
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。